Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Cancer Discovery
|
February 20, 2021
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer
Hongchen Cai, Su Kit Chew, Chuan Li, et al.
Journal of Medicinal Chemistry
|
July 29, 2010
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design
Andrew J Woodhead, Hayley Angove, Maria G Carr, et al.
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Molecular Cancer Therapeutics
|
March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Journal of Medicinal Chemistry
|
May 12, 2016
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening
Alison J-A Woolford, Joseph E Pero, Sridhar Aravapalli, et al.
Nature
|
April 15, 2021
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Andrea C Chaikovsky, Chuan Li, Edwin E Jeng, et al.
Journal of Medicinal Chemistry
|
June 27, 2024
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Nick Palmer, Christopher Agnew, Caroline Benn, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Cancer Discovery
|
February 20, 2021
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer
Hongchen Cai, Su Kit Chew, Chuan Li, et al.
Journal of Medicinal Chemistry
|
July 29, 2010
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design
Andrew J Woodhead, Hayley Angove, Maria G Carr, et al.
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Molecular Cancer Therapeutics
|
March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Journal of Medicinal Chemistry
|
May 12, 2016
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening
Alison J-A Woolford, Joseph E Pero, Sridhar Aravapalli, et al.
Nature
|
April 15, 2021
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Andrea C Chaikovsky, Chuan Li, Edwin E Jeng, et al.
Journal of Medicinal Chemistry
|
June 27, 2024
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Nick Palmer, Christopher Agnew, Caroline Benn, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Page
of 7